KalVista Pharmaceuticals (KALV) Cash from Investing Activities Growth (5y) (2021 - 2025)
KalVista Pharmaceuticals (KALV) Cash from Investing Activities Growth (5y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 30.99% |
| Apr 30, 2025 | -18.45% |
| Oct 31, 2024 | 102.62% |
| Jul 31, 2024 | 92.29% |
| Apr 30, 2024 | -55.13% |
| Jan 31, 2024 | 34.26% |
| Oct 31, 2023 | 165.21% |
| Jul 31, 2023 | 105.57% |
| Apr 30, 2023 | -41.78% |
| Jan 31, 2023 | -69.11% |
| Oct 31, 2022 | 230.79% |
| Jul 31, 2022 | 207.54% |
| Apr 30, 2022 | 346.68% |
| Jan 31, 2022 | -17.68% |
| Oct 31, 2021 | 296.68% |
| Jul 31, 2021 | 222.35% |